2026-07-21T14:00:51Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/173532024-01-23T20:13:25Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Peta, Valentina author Tse, Chantal author Perazzo, Hugo author Munteanu, Mona author Ngo, Yen author Ngo, An author Ramanujam, Nittia author Verglas, Lea author Mallet, Maxime author Ratziu, Vlad author Thabut, Dominique author Rudler, Marika author Thibault, Vincent author Schuppe-Koistinen, Ina author Bonnefont-Rousselot, Dominique author Hainque, Bernard author Imbert-Bismut, Françoise author Merz, Michael author Kullak-Ublick, Gerd author Andrade, Raul author van Boemmel, Florian author Schott, Eckart author Poynard, Thierry author Drug Induced Liver Injury- Groupe Hospitalier Pitié-Salpêtrière author Drug Induced Liver Group of the Injury Safer and Faster Evidence-based Translation consortium author 2017-12-29 There is a clear need for better biomarkers of drug-induced-liver-injury (DILI). We aimed to evaluate the possible prognostic value of ActiTest and FibroTest proteins apoliprotein-A1, haptoglobin and alpha-2-macroglobulin, in patients with DILI. We analyzed cases and controls included in the IMI-SAFE-T-DILI European project, from which serum samples had been stored in a dedicated biobank. The analyses of ActiTest and FibroTest had been prospectively scheduled. The primary objective was to analyze the performance (AUROC) of ActiTest components as predictors of recovery outcome defined as an ALT After adjudication, 154 patients were considered to have DILI and 22 were considered to have acute liver injury without DILI. A multivariate regression analysis (ActiTest-DILI patent pending) combining the ActiTest components without BILI and ALT (used as references), apolipoprotein-A1, haptoglobin, alpha-2-macroglobulin and GGT, age and gender, resulted in a significant prediction of recovery with 67.0% accuracy (77/115) and an AUROC of 0.724 (P We identified that apolipoprotein-A1 and haptoglobin had significant predictive values for the prediction of recovery at 12 weeks in DILI, enabling the construction of a new prognostic panel, the DILI-ActiTest, which needs to be independently validated. 10.1371/journal.pone.0189436 1932-6203 PloS one http://hdl.handle.net/10668/11960 29287080 http://hdl.handle.net/20.500.12105/17353 Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.